Krystal Biotech (KRYS) Payables (2016 - 2026)

Krystal Biotech has reported Payables for 11 years, with the latest figure at $6.5 million in Q2 2026.

• Payables for Q2 2026 came in at $6.5 million, down 8.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $6.5 million (down 8.14% YoY), and the FY2025 annual result was $3.2 million, down 35.05% from the prior year.
• Payables grew to $6.5 million in Q2 2026, from $4.1 million in the prior quarter.
• Over five years, Payables peaked at $9.2 million in Q2 2022 and troughed at $2.1 million in Q3 2025.
• A 5-year average of $5.1 million and a median of $4.7 million in 2023 frame the typical range for Payables.
• The widest annual swing landed in 2022, when Payables soared 629.57%; it then tumbled 62.42% in 2025.
• A 5-year view of Payables shows it stood at $4.0 million in 2022, then rose by 3.79% to $4.1 million in 2023, then increased by 20.64% to $5.0 million in 2024, then slumped by 35.05% to $3.2 million in 2025, then surged by 102.1% to $6.5 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $6.5 million in Q2 2026, $4.1 million in Q1 2026, and $3.2 million in Q4 2025.